Calcific tendinopathy (CT) is a staged, reactive process where pre-calcific changes are followed by a calcific phase (formative, resting, resorptive) and by post-calcific remodelling in which hydroxyapatite-like deposits form and quite often resorb spontaneously. CT is most prevalent in the neck, foot and hip and within the foot. The Achilles is a well-documented site of […]

The mission of PI16 Therapeutics is to improve skin health for the ~4 million Canadian’s suffering from long-term skin diseases, including clinically dry skin, chronic wounds, and severe burns. PI16 Therapeutics aims to produce skin solutions for these individuals by genetically engineering naturally occurring stem-cell like fibroblasts that express the gene Peptidase Inhibitor 16 (Pi16) […]

Ce projet vise à valoriser les résidus lignocellulosiques en créant des biocomposites imprimables en 3D dans une démarche de développement durable afin de capturer le dioxyde de carbone (CO2). L’acide polylactique (PLA), un polymère biodégradable issu se ressources renouvelables, est associé à du biochar produit à partir de résidus forestiers par pyrolyse, et du tanin, […]

This project focuses on developing advanced bioinks enhanced with tiny filler materials to improve 3D bioprinting for tissue engineering. By creating stronger, more printable, and biologically compatible materials, the project aims to help the partner organization advance regenerative medicine technologies. This will support the development of new personalized medical treatments and open up commercial opportunities […]

Le cancer touche en moyenne deux canadiens sur cinq, et chaque personne atteinte du cancer a une chance sur quatre d’en mourir. La recherche contre le cancer est l’une des plus actives dans le monde, et des traitements sont déjà mis à la dispositions des malades. Mais tous les cancers ne sont pas encore curables […]

Secreted protein acidic and rich in cysteine (SPARC) is a protein that is more produced by athletes (muscles) compared to sedentary individuals. We have previously shown that this protein is responsible for some exercise-induced effects, its injections also produce exercise-like effects, and its decrease/absence speeds up ageing. Therefore, SPARC could be an exercise substitute – […]

We are developing a promising new technology based on extracellular vesicles (EVs, often referred to as exosomes), which are natural delivery vehicles produced by cells. These tiny particles have the potential to transform how we treat diseases by delivering therapeutic ingredients directly to where they’re needed in the body. To bring this technology to market […]

This project focuses on developing innovative, biocompatible microrobots for targeted drug delivery, particularly in cancer treatment. By integrating smart hydrogels with magneto-active properties, these tiny robots can navigate the body and deliver highly precise chemotherapy drugs, reducing side effects and improving patient outcomes. Advanced 3D microfabrication techniques, such as two-photon lithography and digital light processing, […]

This project supports the commercialization of INSITE (In Situ Tissue Engineering Bioprinting System), a handheld bioprinting platform developed in the Guenther Lab at the University of Toronto. INSITE enables point-of-care delivery of personalized bioinks directly into skin wounds, offering a novel, autograft-free alternative for treating full-thickness burns and chronic wounds. Current gold-standard treatments rely on […]

This project aims to help bring a new type of filtration membrane—made from a strong and reusable material called PEEK—to the market, specifically for use in making biopharmaceutical drugs. The main goal is to understand the current market, talk to companies and other key stakeholders to identify their specific needs, and develop a clear plan […]

Our project aims to revolutionize the anti-aging skincare market by developing a breakthrough delivery system that enhances the absorption of active ingredients at the cellular level. Traditional skincare products often fail to penetrate deep enough to provide lasting results, leaving consumers with temporary fixes. By leveraging innovative biotechnology, our solution ensures more profound skin rejuvenation, […]

Stroke is a leading cause of disability, affecting 880,000 Canadians, with 109,000 new cases annually and no approved therapies for neuroregeneration. Current standard of care for ischemic stroke includes acute thrombolysis and/or thrombectomy to restore blood flow to the injured tissue, yet these treatments are time sensitive and only apply to specific stroke etiology, leaving […]